SCHEMBL1010027

SCHEMBL1010027

CC(Oc1cccc(CCNCCC(Oc2ccc(Cl)cc2)c2nc3cc(Cl)ccc3o2)c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.42
PPARA Q07869 3/20 0.42
PPARD Q03181 2/20 0.42
EPHX2 P34913 2/20 0.42
LMNA P02545 2/20 0.40
KMT2A Q03164 1/20 0.40
P2RY14 Q15391 1/20 0.39
ADRB3 P13945 7/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
ADRB1 P08588 1/20 0.38
FFAR2 O15552 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010953 0.98 PPARG (0.44) PPARGPPARAPPARDEPHX2LMNA
SCHEMBL1009601 0.95 PPARD (0.40) PPARGPPARAPPARDEPHX2LMNA
SCHEMBL5665973 0.94 PPARA (0.49) PPARGPPARAPPARDEPHX2ADRB3
SCHEMBL1011729 0.89 PPARG (0.44) PPARGPPARAPPARDKMT2AADRB3
SCHEMBL1009397 0.89 PPARA (0.42) PPARGPPARAPPARDEPHX2KMT2A
SCHEMBL5514813 0.88 PPARA (0.53) PPARGPPARAPPARDADRB3
SCHEMBL1009787 0.88 ADRB3 (0.41) PPARGPPARAPPARDEPHX2LMNA
SCHEMBL1009387 0.88 PPARA (0.46) PPARGPPARAPPARDLMNAKMT2A
SCHEMBL1010655 0.88 PPARD (0.44) PPARGPPARAPPARDKMT2AADRB3
SCHEMBL1012107 0.85 PPARA (0.49) PPARGPPARAPPARDADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.